The company, a plasma-based biopharmaceutical with a market cap of nearly $3.1B, isn't selling any shares in the deal and won't receive any proceeds. Warburg Pincus and affiliates will sell the shares.
The number of shares to be sold amounts to about 13.2% of outstanding stock, and common stock outstanding won't change as a result. The offering's expected to close next Monday.
After hours: CBPO flat.
Subscribe for full text news in your inbox